Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.88 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 3/20 | 0.35 |
| ▸ | GABRD | O14764 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL756026 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1ACHE | |
| Valine SCHEMBL296920 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1ACHE | |
| Valine SCHEMBL4340306 | 0.97 | SLC7A5 (0.83) | SLC7A5SLC1A3SLC1A2SLC1A1ACHE | |
| Valine SCHEMBL4340303 | 0.97 | SLC7A5 (0.83) | SLC7A5SLC1A3SLC1A2SLC1A1ACHE | |
| Valine SCHEMBL2213629 | 0.94 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1ACHE | |
| Valine SCHEMBL8516 | 0.94 | — | — | |
| Valine SCHEMBL1813972 | 0.94 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL41225 | 0.94 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL43678 | 0.94 | — | — | |
| Valine SCHEMBL2785563 | 0.94 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011011766-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011007247-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-6399776-B2 | Processes and intermediates in the synthesis of 5-(3-exo-bicyclo[2.2.1]hept-2-yloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyrimidine-2(1H)-one | PFIZER INC | 2002-06-04 | — | — | US | disclosed |
| US-20010041798-A1 | Processes and intermediates in the synthesis of 5-(3-{exo-bicyclo{2.2.1}hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6- tetrahydropyrimidin-2(1H)-one | LACOUR THOMAS G (US) | 2001-11-15 | — | — | US | disclosed |
| US-6274733-B1 | Process and intermediates in the synthesis of 5-(3-[exo-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6-tetrahydro-pyrimidin-2(1H)-one | PFIZER INC. | 2001-08-14 | — | — | US | disclosed |
| US-6022968-A | Processes for the synthesis of 5-(3-[exo-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6-tetrahydr opyrimidin-2(1H)-one | PFIZER INC (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0775119-A1 | PROCESSES AND INTERMEDIATES IN THE SYNTHESIS OF 5-(3- EXO-BICYCLO 2.2.1]HEPT-2-YLOXY]-4-METHOXYPHENYL)-3,4,5,6-TETRAHYDROPYRIMIDIN-2(1H)-ONE | PFIZER INC. (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004253-A1 | PROCESSES AND INTERMEDIATES IN THE SYNTHESIS OF 5-(3-[EXO-BICYCLO[2.2.1]HEPT-2-YLOXY]-4-METHOXYPHENYL)-3,4,5,6-TETRAHYDROPYRIMIDIN-2(1H)-ONE | PFIZER INC. (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | SLC7A5 72/4885SLC1A3 83/4885SLC1A2 68/4885 |
| US-20010041798-A1 | Processes and intermediates in the synthesis of 5-(3-{exo-bicyclo{2.2.1}hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6- tetrahydropyrimidin-2(1H)-one | EXOC3, EXOC4, EXOC1 | SLC7A5 2400/4885SLC1A3 4651/4885SLC1A2 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.